LBRX LB Corp: Rasio rega marang prakiraan pendapatan

LB Pharmaceuticals Inc relies on a diversified pool of international CMOs for the synthesis of complex compounds. The projected P/S multiple, with a metric value of , reflects the dynamics of market expectations. Patents for schizophrenia medications ensure stable revenue, while the non-cyclical demand for antipsychotics makes the business resilient to GDP fluctuations, linking growth to the success of clinical trials.

LB Pharmaceuticals, Inc. - Rasio rega marang prakiraan pendapatan LBRX (periode 04.07.2022 - 13.11.2026)

Rincian metrik keuangan lan pasar LB Corp (LBRX)

- rega pasar lan target rega analis:

Bagan rega LB Pharmaceuticals|LBRX - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Nilai pasar LB Corp|LBRX - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham LB Pharmaceuticals|LBRX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih lbpharma.us|LBRX - Nilai Agregat Aset

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas LB Pharmaceuticals Inc|LBRX - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal LB Pharmaceuticals Inc|LBRX - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku LB Corp|LBRX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan LB Pharmaceuticals|Likuiditas cepet lbpharma.us

- rincian asil keuangan lan kelipatan valuasi:

LBRX - Penghasilan resik|Proyeksi bathi mangsa ngarep LB Pharmaceuticals Inc|LBRX - Pangali P/E|Pangali Forward P/E LB Pharma|LBRX - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA LB Corp|LBRX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan LB Pharmaceuticals|LBRX - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan lbpharma.us|LBRX - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep LB Pharmaceuticals Inc

- indikator pendapatan dodolan lan penghasilan bisnis:

LBRX - Pendapatan reged perusahaan|Prakiraan volume dodolan LB Pharmaceuticals|LBRX - Kapitalisasi marang pendapatan|Multiplikator Forward P/S LB Corp

Ringkesan analisis perusahaan:LB Pharmaceuticals LBRX

The forward P/S measures the ratio of the current market value of LB Pharmaceuticals Inc (LBRX) to expected sales, allowing for an assessment of the degree of optimism priced in amid rising operating expenses. By analyzing the forward P/S based on forecasts, an investor determines the resilience of the capitalization to risks, which is critical for LB Pharmaceuticals Inc (LBRX) during the implementation of robotic biomolecule screening to accelerate drug development.

Pesaing LB Pharmaceuticals Inc

Rasio rega marang prakiraan pendapatan Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ATAI - Rasio rega marang prakiraan pendapatan|GHRS: Rasio rega marang prakiraan pendapatan|MNMD: Multiplikator Forward P/S|CMPS (compasspathways.com) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan DRUG|VNDA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Cybin Inc. (CYBN)|ANRO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NRXP (NRx Pharmaceuticals)|Rega forward marang dodolan CING|Silo Pharma, Inc. - Multiplikator Forward P/S|CPHI - Multiplikator Forward P/S|Clearmind Medicine (CMND) - Rasio rega marang prakiraan pendapatan|Psyence Bio - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan SciSparc Ltd|Multiplikator forward rega marang pendapatan seelostherapeutics.com (SEEL)|Multiplikator Forward P/S VRPX|Multiplikator Forward P/S Karuna Therapeutics Inc (KRTX)